U.S. Healthcare Services Stock News

If you are wondering whether Sonos stock still offers value after a strong run or a rough patch, this article breaks down what the current price might be telling you. Over the past year, the stock has returned 44.4%, compared with a 16.1% gain over the last 30 days, while year to date it is down 13.9% and the 5-year return sits at a 55.5% loss. Recent headlines around Sonos have focused on its role in the consumer audio market and how sentiment has shifted around the stock. These stories...

In early May 2026, Caris Life Sciences reported first-quarter revenue of US$216.17 million versus US$120.92 million a year earlier, with net loss improving to US$0.51 million, while also securing MolDX approval for its Caris ChromoSeq whole genome assay and launching the AI-driven Caris MI Clarity breast cancer prognostic test. Together, these developments highlight Caris’ efforts to broaden its precision oncology portfolio across hematologic malignancies and early-stage breast cancer, while...

In April 2026, Mirion Technologies reported first-quarter revenue of US$257.6 million, up from US$202.0 million a year earlier, but swung from a small net income to a net loss of US$3.4 million, while also reaffirming its full-year 2026 earnings guidance. A key detail for investors is that Mirion’s full-year revenue growth outlook of approximately 22%–24% includes anticipated benefits from foreign exchange movements and recent acquisitions, which helps explain management’s confidence...

Sana Biotechnology, Inc. recently drew attention with heavy pre-earnings options activity and elevated implied volatility, ahead of its first-quarter earnings release and its past May 12, 2026 presentation at the BofA Securities Healthcare Conference. Investors are closely watching how Sana’s engineered cell therapy pipeline, including its collaborations with Beam Therapeutics and Mayo Clinic, might feature in these updates. We’ll now examine how this heightened options activity ahead of...

In the past quarter, EastGroup Properties reported first quarter 2026 earnings that came in well above prior expectations, prompting analysts to raise their forecasts and highlight stronger near-term growth prospects. This earnings surprise has renewed attention on how the company’s logistics-focused portfolio and development pipeline may support its longer-term investment case. With first quarter earnings outperforming expectations, we’ll now examine how this stronger near-term outlook...

Wondering whether NCR Voyix at US$8.09 is starting to look cheap, or still carries too much risk for the price you pay? The stock has moved sharply in the short term, with a 17.4% return over 7 days and 29.2% over 30 days, although returns are negative at 18.0% year to date and 20.4% over 1 year. These recent moves sit against a longer track record that includes 42.7% and 71.8% returns over 3 and 5 years respectively. These figures may reflect shifting sentiment and changing expectations for...

In early May 2026, Innoviva, Inc. reported first-quarter 2026 results, with revenue of US$97.99 million and net income of US$186.6 million, marking a clear turnaround from the prior year’s loss. Around the same time, Innoviva filed a US$207.99 million shelf registration for up to 9,000,000 common shares tied to its employee stock ownership plan, underscoring management’s focus on employee alignment alongside growth in its recurring royalty and Specialty Therapeutics businesses. We’ll now...

Why Catalyst Pharmaceuticals Stock Is On Investors’ Radar Catalyst Pharmaceuticals (CPRX) has drawn attention after a period of strong share-price moves, with returns over the past month, past 3 months and year all in positive territory according to recent performance data. For investors tracking US biopharmaceutical stocks focused on rare diseases, this kind of sustained positive return profile can prompt a closer look at how the current share price relates to earnings, profitability and...

Aurinia Pharmaceuticals (AUPH) has drawn fresh attention after reporting first quarter 2026 results. Revenue was US$77.71 million and net income was US$34.36 million, both higher than the prior year period. See our latest analysis for Aurinia Pharmaceuticals. The earnings beat and reiterated 2026 guidance arrived alongside a 4.9% 90 day share price return and an 86.7% 1 year total shareholder return, suggesting strong recent momentum despite short term share price weakness. If Aurinia’s...

Cimpress plc has reported past third-quarter 2026 results showing sales of US$886.21 million versus US$789.47 million a year earlier, with net income of US$13.84 million compared with a net loss of US$8.24 million and basic earnings per share from continuing operations improving from US$0.33 loss to US$0.57. Over the first nine months to March 31, 2026, Cimpress lifted sales to US$2.79 billion and more than doubled net income to US$70.82 million, highlighting materially stronger...

Jacobs Solutions (NYSE:J) has been selected as part of a joint venture to design five new underground stations for Sydney Metro West. The contract covers integrated engineering design services for Australia’s largest transportation project. The win expands Jacobs Solutions’ global transportation infrastructure footprint, with a focus on high-performance, sustainable mass transit. For investors watching the infrastructure and engineering space, this new Sydney Metro West mandate puts Jacobs...

Stepan Company reported past first-quarter 2026 results showing sales of US$604.51 million versus US$593.26 million a year earlier, but it swung from net income of US$19.71 million to a net loss of US$41.41 million, with basic and diluted loss per share from continuing operations of US$1.81 compared with earnings of US$0.86. Despite the move into loss-making territory, Stepan maintained its shareholder payout by affirming a quarterly dividend of US$0.395 per share, payable on June 15, 2026,...

IHS Holding (NYSE:IHS) has completed the divestment of its 51% stake in Brazilian fiber infrastructure venture I-Systems. The stake has been sold to TIM S.A., marking IHS Holding's exit from this Brazilian optical fiber joint venture. IHS Holding, trading at $8.23, has seen its stock return 12.0% year to date and 44.1% over the past year, while its 3 year return stands at 9.2%. This completed I-Systems divestment gives investors a fresh development to consider alongside those share price...

Albemarle (NYSE:ALB) held its annual shareholder meeting on May 5, 2026. Shareholders approved the board slate, executive compensation package, and auditor ratification. A proposal to remove supermajority provisions for certain affiliated transactions narrowly did not pass. Shareholders backed a proposal to make it easier for investors to call special meetings. Albemarle, a major producer in the lithium and specialty chemicals space, sits at the center of debates around corporate governance...

Encompass Health (EHC) stock is in focus after first quarter 2026 results topped Wall Street expectations, management raised full year revenue and adjusted EPS guidance, and the company continued expanding its inpatient rehabilitation hospital network. See our latest analysis for Encompass Health. The recent 1 day share price return of 2.0% to $107.15 and 7 day share price return of 7.2% suggest momentum has picked up following the earnings beat, higher guidance, new hospital opening and...

Wondering if Maximus stock is offering fair value or a potential bargain right now, especially after a tough stretch for returns. The share price last closed at US$66.66, with Maximus delivering a 1.6% return over the past week and 2.3% over the last month, but a 22.9% decline year to date and a 10.6% decline over the last year hint at changing sentiment. Recent coverage has focused on how Maximus fits into investors' long term portfolios and whether the current price reflects its...

RenaissanceRe Holdings (NYSE:RNR) has appointed Henry Klehm III as Non-Executive Chair, succeeding the company’s long-serving board leader. The board also renewed its share repurchase program, authorizing up to $750 million of buybacks. These moves highlight changes in board oversight and capital allocation at a time when the stock trades around $300.84. RenaissanceRe Holdings comes into this leadership change with the stock at $300.84 and multi year share price gains, including 10.5% year...

If you are wondering whether DNOW stock offers value at today’s price, the key question is how that price lines up with the company’s underlying fundamentals. The stock last closed at US$13.05, with returns of 6.3% over 30 days, a 3.3% decline over 7 days, a 2.3% decline year to date, and a 10.2% decline over 1 year. The 3 year and 5 year returns sit at 43.1% and 19.8% respectively. These mixed returns highlight that sentiment around DNOW can shift over different time frames. This often...

If you are wondering whether Dynex Capital's current share price offers good value or carries more risk than reward, the starting point is to look closely at how it stacks up on valuation. The stock recently closed at US$13.32, with a 7 day return of 2.2% decline, a 30 day return of 5.0%, a year to date return of 5.4% decline, and a 1 year return of 25.5%, which gives you a mix of short term setbacks and longer term gains to weigh up. Recent coverage around Dynex Capital has focused on how...

Xeris Biopharma Holdings (XERS) stock is in focus after the company reported a profitable first quarter of 2026 and raised its full year revenue guidance to US$380 million to US$390 million. See our latest analysis for Xeris Biopharma Holdings. The guidance hike and first quarter profit have come after a mixed period for the stock, with a 12.95% 1 month share price return and a 9.80% year to date share price decline. At the same time, 1 year and 3 year total shareholder returns of 28.49% and...

Sotera Health (SHC) just delivered a busy first quarter, pairing 10% year-over-year revenue growth and a move back to profitability with reaffirmed 2026 guidance and a planned CEO transition. See our latest analysis for Sotera Health. The share price is US$15.67 after a 7.04% 1 month share price return. However, the 90 day share price return of 11.72% and year to date share price return of 11.42% suggest recent momentum has cooled. Even so, the 1 year total shareholder return of 18.44% and 3...

Inflation jitters, higher energy costs and uneven global growth are putting a spotlight on company quality. When price pressures, shifting trade flows and rate expectations keep markets on edge, stocks with high return on equity, solid past performance and strong balance sheets can offer a more direct way to focus on business strength rather than noise. This article uses our Solid Balance Sheet and Fundamentals screener to highlight 3 stocks that fit this quality filter, helping you focus on...

Why AtriCure (ATRC) Is On Investors’ Radar Today AtriCure (ATRC) has drawn fresh attention as investors reassess the stock after a difficult stretch, with negative returns over the past month, past 3 months, year to date, and over the past year. See our latest analysis for AtriCure. At a share price of $27.80, AtriCure has seen weaker short term momentum, with a 30 day share price return of a 3.77% decline and a 1 year total shareholder return of a 10.84% loss pointing to prolonged...

Rising inflation surprises, volatile energy and food prices, and mixed signals on growth are keeping markets jumpy, while the world’s appetite for electricity-intensive AI and low carbon power keeps building. For investors, that combination puts long term, round the clock clean energy at the center of many big spending plans. The Nuclear Renaissance screener focuses on companies tied to this push for reliable, carbon free power linked to major infrastructure commitments rather than short term...